Inpatient mortality ‐ not measured
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of delirium
It is very uncertain whether prophylactic cholinesterase inhibitor changes incidence of delirium DSM‐IV criteria, DSI, CAM, compared with placebo (very low certainty).
1 finding from 1 review
Duration of delirium ‐ not measured
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of delirium
1 finding from 1 review
Any adverse event (combined: diarrhoea, urinary tract infection, falls, dizziness, agitations) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in any adverse event (combined: diarrhoea, urinary tract infection,… compared with placebo (moderate certainty).
1 finding from 1 review
ADL outcome · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Overall dementia severity (cognition and function combined) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Memory ‐ not measured · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review
QoL · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Depressive symptoms · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Mental health outcomes · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
IADL · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Change in capacity for activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to lower physician rated global impression tests (no change or worse compared… compared with placebo (moderate certainty).
1 finding from 1 review
Behavioural symptoms (change from baseline at 26 weeks measured using various scales) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Acceptability · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review